These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 24171960

  • 1. [The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment].
    Li F, Xu Y, An G, Hu LP, Zhang YR, Li ZJ, Yuan WP, Cheng T, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):862-7. PubMed ID: 24171960
    [Abstract] [Full Text] [Related]

  • 2. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H, Qi X, Jiang A, Xu W, Young T, Reece D.
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [Abstract] [Full Text] [Related]

  • 3. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H, Ning Y, Qi X, Yeung J, Xu W.
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [Abstract] [Full Text] [Related]

  • 4. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H, Meng H, Wang J, Lou Y, Zhou Y, Lin P, Li F, Liu L, Xu H, Yang M, Jin J.
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [Abstract] [Full Text] [Related]

  • 5. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A.
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [Abstract] [Full Text] [Related]

  • 6. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
    Deng P, Zhou YL, Wei YL, Li P, Li F.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
    [Abstract] [Full Text] [Related]

  • 7. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F, Hao M, Li Z, Zang M, Zhou D, Gu Z, Ru K, Wang J, Cheng T, Qiu L.
    Oncotarget; 2015 Apr 20; 6(11):9434-44. PubMed ID: 25831238
    [Abstract] [Full Text] [Related]

  • 8. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
    Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A.
    Leuk Lymphoma; 2017 Sep 20; 58(9):1-15. PubMed ID: 28092996
    [Abstract] [Full Text] [Related]

  • 9. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D.
    J Clin Oncol; 2013 Dec 01; 31(34):4325-32. PubMed ID: 24145347
    [Abstract] [Full Text] [Related]

  • 10. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
    Li Q, An G, Li CW, Xu Y, Deng SH, Liu XP, Qi JY, Wang YF, Zou DH, Zhao YZ, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr 01; 32(4):217-20. PubMed ID: 21569701
    [Abstract] [Full Text] [Related]

  • 11. [Chromosome 13q deletion detected by interphase FISH in multiple myeloma: a study of 100 cases in China].
    Li Q, Lu Y, Wang YF, Liu XP, Qi JY, Zou DH, Zhao YZ, Qiu LG.
    Zhonghua Yi Xue Za Zhi; 2009 Jul 28; 89(28):1979-82. PubMed ID: 19950573
    [Abstract] [Full Text] [Related]

  • 12. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P.
    Clin Lymphoma Myeloma Leuk; 2013 Apr 28; 13(2):123-30. PubMed ID: 23291040
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of 1p deletion for multiple myeloma: a meta-analysis.
    Ouyang J, Gou X, Ma Y, Huang Q, Jiang T.
    Int J Lab Hematol; 2014 Oct 28; 36(5):555-65. PubMed ID: 24460694
    [Abstract] [Full Text] [Related]

  • 14. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.
    Am J Hematol; 2016 Nov 28; 91(11):E473-E477. PubMed ID: 27508939
    [Abstract] [Full Text] [Related]

  • 15. [Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma].
    Smejkalová J, Vranová V, Oltová A, Kuglík P, Filková H, Heinigová J, Kovárová L, Adam Z, Krejcí M, Pour L, Büchler T, Svobodník A, Vostrejsová S, Kalábová V, Vorlícek J, Penka M, Hájek R.
    Cas Lek Cesk; 2005 Nov 28; 144(7):483-8. PubMed ID: 16161543
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
    Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B.
    Br J Haematol; 2003 Jan 28; 120(1):44-52. PubMed ID: 12492575
    [Abstract] [Full Text] [Related]

  • 17. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH, Korean Multiple Myeloma Working Party (KMMWP).
    Ann Hematol; 2014 Aug 28; 93(8):1353-61. PubMed ID: 24671365
    [Abstract] [Full Text] [Related]

  • 18. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
    Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gonzalez D, Walker BA, Hockley SL, Wardell CP, Gregory WM, Child JA, Jackson GH, Davies FE, Morgan GJ, NCRI Haematology Oncology Studies Group.
    Genes Chromosomes Cancer; 2011 Oct 28; 50(10):765-74. PubMed ID: 21961181
    [Abstract] [Full Text] [Related]

  • 19. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ, Li JY, Zhu Y, Wang XW, Qiu HR, Yang RF, Xu W, Xu JR, Lu H.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb 28; 26(1):102-5. PubMed ID: 19199264
    [Abstract] [Full Text] [Related]

  • 20. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
    He H, Fu W, Jiang H, Du J, Zhou L, Zhang C, Xi H, Li R, Hou J.
    Leuk Res; 2015 May 28; 39(5):515-9. PubMed ID: 25817540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.